BioSpace News Archive

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced positive Phase 2b data of encaleret in patients with autosomal dominant hypocalcemia type 1.

NightHawk Biosciences announced the appointment of Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services.

Akero Therapeutics, Inc. announced that it will present oral and poster presentations at the Keystone Symposium on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies, being held in Keystone, Colorado, June 12-16.

Aeterna Zentaris Inc. announced its Autoimmunity Modifying Biologicals program has achieved pre-clinical proof-of-concept for the potential treatment of neuromyelitis optica spectrum disorder, a chronic autoimmune disorder of the brain and spinal cord dominated by inflammation of the optic nerve and spinal cord and which can be fatal in approximately 30% of patients within five years of diagnosis.

META Pharmaceuticals, China’s first immunometabolism-based small-molecule drug discovery company, announced two consecutive Seed and Pre-A funding rounds totaling 15 million USD.

Regulus Therapeutics Inc today announced the dosing of the first healthy volunteer in the Phase 1 SAD study of RGSL8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

IceCure Medical Ltd. announced that its wholly-owned subsidiary, IceCure MedTech Co., Ltd., signed an exclusive distribution agreement for IceSense3 cryoablation systems with Shanghai Medtronic Zhikang Medical Devices Co. Ltd., an affiliate of Medtronic plc and Beijing Turing Medical Technology Co. Ltd.

Enteris BioPharma, Inc. announced today that two posters describing clinical studies of oral formulations of leuprolide developed utilizing Enteris’ proprietary Peptelligence® platform are being presented at the annual meeting of The Endocrine Society (ENDO 2022) taking place June 11-14, 2022, in Atlanta.

Evecxia Therapeutics, a clinical stage biopharmaceutical company dedicated to realizing the therapeutic potential of serotonin synthesis amplification for the treatment of brain disorders, today announced that Joseph M. Patti, Ph.D., has been appointed President and Chief Executive Officer.

Biotech Acquisition Company (NASDAQ: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company based in South San Francisco, Calif., today announced that they have mutually agreed to terminate the previously announced Agreement and Plan of Merger (the “Merger Agreement”), effective immediately.